STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2229 by analyst upside · 2026-06-27
GILD
Gilead Sciences, Inc.
Healthcare · Market Cap $159B · P/E 17.4x
ANALYST PRICE TARGET
+23.2%
implied upside to consensus target
Current Price $127.88
Consensus Target $157.57
Bull Target $180.0
Bear Target $122.0
Analysts Covering 28
ANALYST CONSENSUS — BUY
Strong Buy
5
Buy
16
Hold
7
Sell
0
52-Week Low $106.84
52-Week High $157.29
YTD Return +6.5%
FUNDAMENTALS
Market Cap $159B
P/E Ratio (TTM) 17.4x
Forward P/E 13.2x
EPS (TTM) $7.36
PEG Ratio 2.14
Dividend Yield 2.65%
Revenue (TTM) $29.7B
Profit Margin 31.0%
52-WEEK RANGE
52-Week Low $106.84
52-Week High $157.29
Current Price $127.88
Bear Target $122.0
Bull Target $180.0
● Now $127.88 ● Target $157.57
TRADING DATA
Avg Volume 6.9M
YTD Return +6.5%
Analyst Count 28
Consensus Buy
Upside to Target +23.2%
Last Updated 2026-06-27

ANALYST SUMMARY

Gilead Sciences, Inc. (GILD) is currently trading at $127.88 with a Wall Street consensus price target of $157.57, implying potential upside of 23.2% over the next 12 months. 28 analysts currently cover GILD, with a consensus rating of Buy — 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $180.0, while the most cautious has a target of $122.0.

GILD operates in the Healthcare sector with a market capitalisation of $159B. The stock is up 6.5% year-to-date and is currently trading near the lower end of its 52-week range of $106.84 – $157.29.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for GILD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Cantor Fitzgerald reit
Overweight → Overweight 2026-06-16 40% win rate (10 calls)
Maxim Group ↑ Upgrade
Hold → Buy 2026-05-20 28% win rate (40 calls)
Truist Securities reit
Buy → Buy 2026-05-08 Building track record
RBC Capital — Reiterated
Sector Perform → Sector Perform 2026-05-08 Building track record
Citigroup — Reiterated
Buy → Buy 2026-04-13 Building track record
Morgan Stanley — Reiterated
Overweight → Overweight 2026-04-10 Building track record
Jefferies ● Initiated
Buy 2026-03-10 50% win rate (6 calls)
Needham reit
Buy → Buy 2026-02-23 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →